Privia Health Group Files 8-K

TL;DR

PRVA filed an 8-K today, but it's light on details. Keep an eye out for more info.

AI Summary

Privia Health Group, Inc. filed an 8-K on September 23, 2025, to report other events. The filing does not contain specific details about the nature of these events, the dollar amounts involved, or any new agreements or changes in executive leadership.

Why It Matters

This 8-K filing indicates that Privia Health Group, Inc. has reported an event requiring immediate disclosure to the SEC, though the specifics are not detailed in the provided text.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and lacks specific material information that would immediately impact the company's risk profile.

Key Players & Entities

• Privia Health Group, Inc. (company) — Registrant
• September 23, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-40365 (filing_id) — Commission File Number
• 950 N. Glebe Rd., Suite 700 (address) — Principal Executive Offices
• Arlington, Virginia (location) — Principal Executive Offices City and State

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value per share PRVA The Nasdaq Glo
• $100 million — business from Evolent Health, Inc. for $100 million in cash at closing and up to an additio
• $13 million — cash at closing and up to an additional $13 million subject to final performance under the

Filing Documents

• prva-20250923.htm (8-K) — 29KB
• ex-991xpressreleasedatedse.htm (EX-99.1) — 15KB
• privialogo.jpg (GRAPHIC) — 8KB
• 0001759655-25-000099.txt ( ) — 178KB
• prva-20250923.xsd (EX-101.SCH) — 2KB
• prva-20250923_lab.xml (EX-101.LAB) — 22KB
• prva-20250923_pre.xml (EX-101.PRE) — 13KB
• prva-20250923_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On September 23, 2025, Privia Health Group, Inc. (the "Company") issued a press release announcing the entry into a definitive agreement to acquire an Accountable Care Organization business from Evolent Health, Inc. for $100 million in cash at closing and up to an additional $13 million subject to final performance under the Medicare Shared Savings Program for 2025. Subject to applicable regulatory approvals and other customary closing conditions, the transaction is expected to close in the fourth quarter of 2025.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as "aims," "anticipates," "assumes," "believes," "estimates," "expects," "forecasts," "future," "intends," "likely," "may," "outlook," "plans," "potential," "projects," "seeks," "strategy," "targets," "trends," "will," "would," "could," "should," and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things: our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full-year guidance for 2025. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements. Factors related to these risks and uncertainties include, but are not limited to: the heavily regulated industry in which we operate, and any failure by us or our medical groups to comply with the extensive applicable healthcare laws and government regulations; the complexity of the legal framework governing our relationships with Medical Groups, some of which we do not own, and Privia providers, and the impact of legal challenges or shifting interpretations of applicable laws; the exe

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Privia Health Group, Inc. Press Release Dated September 23, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRIVIA HEALTH GROUP, INC. Date: September 23, 2025 By: /s/ David Mountcastle Name: David Mountcastle Title: Executive Vice President, Chief Financial Officer and Authorized Officer

View Full Filing

View this 8-K filing on SEC EDGAR